Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
| Revenue (TTM) | $46.59B |
| Gross Profit (TTM) | $26.45B |
| EBITDA | $11.87B |
| Operating Margin | 14.10% |
| Return on Equity | 12.30% |
| Return on Assets | 5.59% |
| Revenue/Share (TTM) | $26.79 |
| Book Value | $29.89 |
| Price-to-Book | 3.50 |
| Price-to-Sales (TTM) | 4.01 |
| EV/Revenue | 4.481 |
| EV/EBITDA | 20.79 |
| Quarterly Earnings Growth (YoY) | -47.50% |
| Quarterly Revenue Growth (YoY) | 13.00% |
| Shares Outstanding | $1.74B |
| Float | $1.73B |
| % Insiders | 0.49% |
| % Institutions | 82.54% |
Volatility is currently expanding
ABT is expanding across diabetes care, oncology diagnostics and heart devices, with new launches and acquisitions creating multiple growth paths to watch.
Abbott Laboratories ABT has a stronger earnings setup after a second-quarter beat and a higher profit outlook. The question is whether that improvement is enough to justify buying the stock with valuation upside looking limited.
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening – BRISBANE, Calif. and ABBOTT PARK, Ill.
Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.
ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Abbott Laboratories (NYSE:ABT) both recently posted earnings that show two healthcare giants moving in opposite strategic directions.
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.
Abbott Laboratories has rallied sharply since my last "Buy" rating in May. Strength in its core Medical Devices business and the recently acquired Exact Sciences should keep driving strong growth for the company. Abbott Laboratories enjoys an A+ S&P credit rating with a stable outlook.
Demand for Abbott's medical devices and diagnostic tests is rising. The company has increased its dividend for 54 straight years.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABT and any ticker you trade — then tracks every position and per-strategy win rate.
